DMAC | NASDAQ
$8.01
-$0.03 | -0.37%
TREND SIGNAL:
|2026-10-15
|2026-10-15
Company Overview:
Market Cap:
$431.55M
Trailing PE:
N/A
FWD PE:
—
Payout Ratio (TTM):
—
52-Week Range:
$5.25 - $10.42
10 Year DMAC Performance Metrics:
Total Return (with DRIP):
103.3% (7.35% CAGR)
Total Return (no DRIP):
103.3% (7.35% CAGR)
Share Price:
103.3% (7.35% CAGR)
Yield on Cost (with DRIP):
—
Total Invested:
$10,000
Total Value (with DRIP):
$20,330
Total Return $ (with DRIP):
$10,330
DMAC Total Return
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
DMAC Price Chart
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
All
Unlock All Reports & Research Dividend Stocks like a BOSS!
Get 3 Months Free with Annual Plan
Get 3 Months Free with Annual Plan
PRO
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
40% Lifetime Discount
Most Popular
PREMIUM
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
40% Lifetime Discount
ULTRA
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
40% Lifetime Discount
PRO
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
Combined 55% Lifetime Discount
DMAC Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
DMAC Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Shares Outstanding CAGR:1Y: 25.46%2Y: 18.98%5Y: 23.46%10Y: 28.50%
DMAC Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Stock-Based Comp CAGR:1Y: 45.01%2Y: 58.86%5Y: 20.18%10Y: 33.56%
DMAC Expenses CAGR:1Y: -50.00%2Y: 0.00%5Y: -5.59%10Y: 107.78%
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
DMAC Actual Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Ratios, Profit Margins & Return on Capital:
DMAC Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Price To Sales Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DMAC Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
Projected Future Returns & Dividends for DMAC
Based on past 10-year performance, here are DMAC growth metrics:
Share price CAGR of +7.35%
Dividend CAGR of +0%
Using DMAC CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| DMAC (DRIP) | DMAC - No DRIP | |
|---|---|---|
| Current Price | $8.01 | $8.01 |
| Start Shares | 1,248.44 | 1,248.44 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 1,248.44 | 1,248.44 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $8.01 | $8.01 |
| Total Dividends | $0 | $0 |
| Final Value | $10,000 | $10,000 |
Estimated Future Value + Dividends - DMAC
NOTE: Above numbers are our estimate based on DMAC's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Get 3 Months Free with Annual Plan
Get 3 Months Free with Annual Plan
PRO
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
40% Lifetime Discount
Most Popular
PREMIUM
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
40% Lifetime Discount
ULTRA
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
40% Lifetime Discount
PRO
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
Combined 55% Lifetime Discount
Company Info
DiaMedica Therapeutics Inc. (DMAC) had its IPO on 2012-08-03, and is traded on NASDAQ stock exchange.
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
DMAC website: https://www.diamedica.com
Get Full Access to All Reports with DRIPCalc PRO
Get 3 Months Free with Annual Plan
Get 3 Months Free with Annual Plan
PRO
$19/mo
$11.40/mo
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
40% Lifetime Discount
Most Popular
PREMIUM
$32/mo
$19.20/mo
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
40% Lifetime Discount
ULTRA
$64/mo
$38.40/mo
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
40% Lifetime Discount
PRO
$171 ($14.25/mo)
$102.60/yr ($8.55/mo)
7-day free trial
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo)
$172.80/yr ($14.40/mo)
7-day free trial
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo)
$345.60/yr ($28.80/mo)
7-day free trial
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
Combined 55% Lifetime Discount
Loading signals…
DCF Model — DMAC
Value from:
🔒 Upgrade to unlock
The full DCF valuation — fair value, implied growth and the price path — is a paid feature.
Upgrade
Pay up to today
—
vs current price $8.01
—
Cash flow & implied price by year
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
| Year | FCF | Implied price |
|---|
Sensitivity — fair value: growth ↓ × target return →
